NCT00272051View on ClinicalTrials.gov

XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy

PHASE3CompletedINTERVENTIONAL

Enrollment

620

Participants

Timeline

Start Date

July 31, 2002

Study Completion Date

May 31, 2004

Conditions

MetastasesColorectal NeoplasmsColorectal Carcinoma

Interventions

DRUG

SR57746A

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY